Hanx Biopharmaceuticals Announces Four Oncology Poster Presentations for AACR 2026

Hanx Biopharmaceuticals (Hanx) has disclosed that four of its oncology research programmes have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for 17–22 April 2026 at the San Diego Convention Center, California.

HX044 – Next-Generation CTLA-4/SIRPα Fusion Protein • Abstract: “Non-Clinical PK and PD Modeling to Assess the Therapeutic Window of HX044, a Novel CTLA-4 × CD47 BsAb, as Comparison with Ipilimumab” • Session: 14:00–17:00 (PT), 21 April 2026, Poster Section 6, Board #21, Abstract #5549 HX044 is designed to target both CTLA-4 and CD47, aiming to deplete regulatory T-cells within the tumour micro-environment and address resistance to existing PD-1/ICI therapies.

HX116 – First-in-Class PD-L1×VEGF Bispecific ADC • Abstract: “Explore a Novel Multi-Modal PD-L1×VEGF-ADCs (HX116) for Potential Enhanced Potency for Solid Tumor Treatments” • Session: 14:00–17:00 (PT), 21 April 2026, Poster Section 44, Board #2, Abstract #6536 Pre-clinical data indicate that HX116 delivers superior anti-tumour activity versus its parental bispecific antibody by combining direct cytotoxicity with immunogenic cell-death-driven immune activation.

HX112 – Multi-Modal PD-L1-Targeted ADC • Abstract: “A Novel Multi-Modal PD-L1-ADC Could Be a Potential Candidate Treatment for Pan-Solid Tumors with Enhanced Tumor-Specificity” • Session: 09:00–12:00 (PT), 22 April 2026, Poster Section 6, Board #30, Abstract #6949 HX112 is being developed for a broad range of solid tumours, leveraging a PD-L1-focused payload to improve tumour specificity.

3D Tumour Organoid ADC Evaluation Platform • Abstract: “3D-Tumor Organoid, over 2D-Cell, Is More Predictive of In Vivo Anti-Cancer Pharmacology in Assessing ADC Candidates” • Session: 09:00–12:00 (PT), 21 April 2026, Poster Section 12, Board #26, Abstract #4448 The company’s preclinical platform demonstrates that 3D tumour organoids provide stronger correlation with in-vivo anti-tumour efficacy than traditional 2D cell cultures, supporting improved candidate screening for antibody-drug conjugates.

Hanx stated it will continue to advance its immunotherapy pipeline to offer more effective and safer oncology treatments. Shareholders are reminded that these assets remain under development and may not ultimately reach the market, in accordance with Rule 18A.05 of the HKEX Listing Rules.